RxDoctor Payments Data

Paige Lombard, NP

Family · Warsaw, INNPI 1770005829

Payments from drug & device makers

$8,223in general payments, 2019–2025

Across 443 payments — averaging $18.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$1K
  • AbbVie$777
  • Sanofi$650
  • Regeneron Healthcare Solutions, Inc.$378
  • Pfizer$284
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$8,12999%
  • Education$941%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,223 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$18,487
Medicare patients
75
Services billed
1,238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$58,902
Breo ElliptaFluticasone/Vilanterol70$46,721
NucalaMepolizumab12$45,147
Breztri AerosphereBudesonide/Glycopyr/Formoterol60$42,123
Spiriva RespimatTiotropium Bromide28$27,556
SymbicortBudesonide/Formoterol Fumarate47$16,629
Advair HfaFluticasone Propion/Salmeterol24$12,032
DuleraMometasone/Formoterol31$10,734
Fluticasone-SalmeterolFluticasone Propion/Salmeterol63$10,229
Qvar RedihalerBeclomethasone Dipropionate14$4,981
Arnuity ElliptaFluticasone Furoate17$4,848
Albuterol Sulfate HfaAlbuterol Sulfate157$4,109
Wixela InhubFluticasone Propion/Salmeterol14$3,417
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate47$3,192
Famotidine226$2,740

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Nucala, Arnuity Ellipta$1,409$155,618155 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,823$58,751107 claims
Boehringer IngelheimSpiriva Respimat$205$27,55628 claims
MerckDulera$13$10,73431 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler, Albuterol Sulfate$143$7,34436 claims
Upsher-smith Laboratories LLCTopiramate$12$9714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.

Other family in Warsaw

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →